A randomized trial of aspirin to prevent colorectal adenomas

New England Journal of Medicine

Volumn 348, Issue 10, 2003, Pages 891-899

  Baron, John A ^a,b,p   Cole, Bernard F ^a   Sandler, Robert S ^c   Haile, Robert W ^d   Ahnen, Dennis ^e,f   Bresalier, Robert ^g   McKeown Eyssen, Gail ^h   Summers, Robert W ⁱ   Rothstein, Richard ^b   Burke, Carol A ^j   Snover, Dale C ^k   Church, Timothy R ^l   Allen, John I ^m,n   Beach, Michael ^b   Beck, Gerald J ^j   Bond, John H ^e,m   Byers, Tim ^f   Greenberg, E Robert ^a,b   Mandel, Jack S ^o   Marcon, Norman ^h   Mott, Leila A ^b   Pearson, Loretta ^b   Saibil, Fred ^h   Van Stolk, Rosalind U ^j   more..

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^g HENRY FORD HEALTH SCIENCES CENTER   (United States)

^h UNIVERSITY OF TORONTO   (Canada)

ⁱ UNIVERSITY OF IOWA   (United States)

^j LERNER RESEARCH INSTITUTE   (United States)

^k FAIRVIEW SOUTHDALE HOSPITAL   (United States)

^l UNIVERSITY OF MINNESOTA   (United States)

^m UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

ⁿ Minnesota Gastroenterology   (United States)

^o EMORY UNIVERSITY   (United States)

^p Biostatistics and Epidemiology   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FOLIC ACID; PLACEBO;

ADULT; ADVANCED CANCER; AGED; ANAMNESIS; ARTICLE; CALCULATION; CANCER INVASION; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL PROTOCOL; CLINICAL TRIAL; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL CANCER; COLORECTAL TUMOR; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DYSPLASIA; ENDOSCOPY; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HISTOPATHOLOGY; HUMAN; INCIDENCE; LARGE INTESTINE; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK; SIDE EFFECT; STATISTICAL MODEL; STROKE; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR VOLUME;

ADENOMA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; COLONIC POLYPS; COLONOSCOPY; COLORECTAL NEOPLASMS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RECURRENCE; RISK;

EID: 0037421985     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa021735     Document Type: Article

References (30)

1. Arber N. Do NSAIDs prevent colorectal cancer? Can J Gastroenterol 2000;14:299-307.
2. IARC handbooks of cancer prevention. Vol. 1. Non-steroidal anti-inflammatory drugs. Lyons, France: International Agency for Research on Cancer, 1997.
3. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313-6.
4. Labayle D, Fischer D, Vielh P, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991;101:635-9.
5. Ladenheim J, Garcia G, Titzer D, et al. Effect of sulindac on sporadic colonic polyps. Gastroenterology 1995;108:1083-7.
6. Steinbach G, Lynch PM, Phillips RKS, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-52.
7. Peipins LA, Sandler RS. Epidemiology of colorectal adenomas. Epidemiol Rev 1994; 16:273-97.
8. Neugut AI, Jacobson JS, DeVivo I. Epidemiology of colorectal adenomatous polyps. Cancer Epidemiol Biomarkers Prev 1993;2:159-76.
9. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994;121:241-6.
10. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-90.
11. Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 1993;85:1220-4.
12. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis. J Natl Cancer Inst 1998;90:1529-36.
13. Xu XM, Sansores-Garcia L, Chen XM, Matijevic-Aleksic N, Du M, Wu KK. Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate. Proc Natl Acad Sci U S A 1999;96:5292-7.
14. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition ofcyclooxygenase-2. Nat Rev Cancer 2001; 1:11-21.
15. Shiff SJ, Rigas B. The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal antiinflammatory drugs (NSAIDs). J Exp Med 1999;190:445-50.
16. Rex DK, Cutler CS, Lemmel GT, et al. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology 1997;112:24-8.
17. Hixson LJ, Fennerty MB, Sampliner RE, Garewal HS. Prospective blinded trial of the colonoscopic miss-rate of large colorectal polyps. Gastrointest Endosc 1991;37:125-7.
18. Hawkey CJ. Nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology 2000;119:521-35.
19. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 2000;321:1183-7.
20. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106. [Erratum, BMJ 1994;308:1540.]
21. Smalley W, Ray WA, Daugherty J, Griffin MR. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. Arch Intern Med 1999;159:161-6.
22. Rosenberg L, Louik C, Shapiro S. Nonsteroidal antiinflammatory drug use and reduced risk of large bowel carcinoma. Cancer 1998;82:2326-33.
23. Sample D, Wargovich M, Fischer SM, et al. A dose-finding study of aspirin for chemoprevention utilizing rectal mucosal prostaglandin E(2) levels as a biomarker. Cancer Epidemiol Biomarkers Prev 2002;11:275-9.
24. Puffin MTIV, Krishnan K, Rock CL, et al. Suppression of human colorectal mucosal prostaglandins: determining the lowest effective aspirin dose. J Natl Cancer Inst 1997;89:1152-60.
25. Barnes CJ, Hamby-Mason RL, Hardman WE, Cameron IL, Speeg KV, Lee M. Effect of aspirin on prostaglandin E2 formation and transforming growth factor alpha expression in human rectal mucosa from individuals with a history of adenomatous polyps of the colon. Cancer Epidemiol Biomarkers Prev 1999;8:311-5.
26. Kabashima K, Saji T, Murata T, et al. The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest 2002;109:883-93.
27. Krause W, DuBois RN. Eicosanoids and the large intestine. Prostaglandins Other Lipid Mediat 2000;61:145-61.
28. Shureiqi I, Lippman SM. Lipoxygenase modulation to reverse carcinogenesis. Cancer Res 2001;61:6307-12.
29. Provenzale D. The cost-effectiveness of aspirin for chemoprevention of colorectal cancer. Gastroenterology 2002;122:230-3.
30. Ladabaum U, Chopra CL, Huang G, Scheiman JM, Chernew ME, Fendrick AM. Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer: a cost-effectiveness analysis. Ann Intern Med 2001; 135:769-81.